Insider trading or pure speculation?, page-36

Then why organise the meeting now after nearly a year of supposedly talking to the pharma companies?

There really isn't anything these new experts can say that the experts inside the pharma companies haven't already told BIT.

Everything comes back to the original problem and that is BIT009 failed its primary objective. Yes there might be some encouraging signs that BIT225 does something positive, but it is nowhere near clear cut enough to progress to a phase 3 trial. BIT either has to run another complex and expensive trial to gather the data to convince the pharma companies that BIT225 is worthwhile, or they have to put BIT225 on hold.

Either way if you are MM you need cover given what you have said previously to the shareholders about BIT225 prospects. Where do you get this cover - a panel of experts.